Henry Schein (HSIC) is back on investors’ radar after recent share price moves, with the stock showing mixed returns over the past year and over longer periods, which may prompt a closer look at its fundamentals.
See our latest analysis for Henry Schein.
Recent trading has been choppy, with a 1-day share price return of 1.23% and a 30-day share price return of a 7.82% decline. However, the 1-year total shareholder return of 11.04% indicates that longer term holders have still seen gains, while 3 and 5 year total shareholder returns show mixed results, hinting that momentum has been fading rather than building recently.
If Henry Schein’s recent moves have you reassessing healthcare exposure, it can be useful to see what else is setting up interestingly in the sector through 37 healthcare AI stocks
With Henry Schein trading at $73.94 and sitting at a 56% discount to an estimated intrinsic value and about 22% below the average analyst target, you have to ask: is this a genuine opportunity, or is the market already factoring in future growth?
Most Popular Narrative: 17.8% Undervalued
Henry Schein’s last close at $73.94 sits below a narrative fair value of $90, putting the focus firmly on what is driving that gap.
The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings, and expects over 50% of non-GAAP operating income to come from these segments, supporting structurally higher gross margins and likely driving earnings expansion. Investments in digital workflow, AI solutions, and integrated cloud-based practice management platforms are accelerating recurring SaaS revenues and client retention. This positions Henry Schein to benefit from the ongoing digital transformation of healthcare, which should support both revenue growth and improved margins.
Want to see what sits behind that $90 fair value? The narrative leans on steady top line assumptions, firmer margins, and a future earnings multiple that might surprise you.
The popular narrative applies a 6.98% discount rate and ties its view on value to expectations for moderate revenue growth, higher profit margins and a lower P/E multiple on future earnings than the broader US healthcare space, all while assuming ongoing share count reduction. Those inputs, taken together, are what bridge today’s price to the $90 figure, rather than any single headline metric.
Result: Fair Value of $90 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that $90 fair value hinges on smoother execution than Henry Schein may deliver. Competitive pricing pressure and staffing constraints are both capable of denting the margin story.
Find out about the key risks to this Henry Schein narrative.
Next Steps
With both risks and rewards in play for Henry Schein, it makes sense to move quickly and review the full picture for yourself with 4 key rewards and 2 important warning signs
Looking for more investment ideas?
If Henry Schein has sharpened your focus, do not stop here. Widen your watchlist with a few more focused stock ideas built from clear, data driven filters.
- Target reliability by scanning companies that emphasise financial resilience and low risk profiles through the 67 resilient stocks with low risk scores.
- Hunt for quality at a possible discount by reviewing companies that screen well on fundamentals via the screener containing 25 high quality undiscovered gems.
- Prioritise balance sheet strength by assessing companies highlighted in the solid balance sheet and fundamentals stocks screener (39 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com